• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Margaret A. Shipp, M.D.


  • Ouyang J, Pl├╝tschow A, Pogge von Strandmann E, Reiners KS, Ponader S, Rabinovich GA, Neuberg D, Engert A, Shipp MA.Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma.Blood. 2013 Apr 25;121(17):3431-3.
  • Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J, Shipp MA.BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.Mol Cell Biol. 2013 Feb;33(4):845-57.
  • Laderach DJ, Gentilini L, Giribaldi L, Cardenas Delgado V, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez ES, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA.A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.Cancer Res. 2012 Oct 29.
  • Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, Croci MC, Shipp MA, Mesri EA, Albini A, Rabinovich GA.Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.J Exp Med. 2012 Oct 22;209(11):1985-2000.
  • Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, Zhou F, Green MR, Chen L, Monti S, Marto JA, Shipp MA, Danial NN.Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.Cancer Cell. 2012 Oct 16;22(4):547-60.
  • Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Currie T, Dogan A, Kutok JL, Beroukhim R, Neuberg D, Habermann TM, Getz G, Kung AL, Golub TR, Shipp MA.Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.Cancer Cell. 2012 Sep 11;22(3):359-72.
  • Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP.Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program.Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2873-8.
  • Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA.Viral induction and targeted inhibition of galectin-1 in EBV+ post-transplant lymphoproliferative disorders.Blood. 2011 Feb 7.
  • Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, Shipp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T.The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker to identify c-MYC translocated lymphomas.Haematologica. 2010 Dec;95(12):2056-62.
  • Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA.Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Blood. 2010 Oct 28;116(17):3268-77.
  • Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, Shipp MA.MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.Clin Cancer Res. 2010 Apr 1;16(7):2122-30.
  • Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.Inhibition of Syk with fostamatinib disodium has significant clinical activity in non Hodgkin's lymphoma and chronic lymphocytic leukemia.Blood. 2010 Apr 1;115(13):2578-85.
  • Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA.BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.Blood. 2009 Dec 17;114(26):5315-21.
  • Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA.BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response.Mol Cell. 2009 Oct 9;36(1):110-20.
  • Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA.BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response.Mol Cell..
  • Wu D, Dutra B, Lindeman N, Takahashi H, Takeyama K, Harris NL, Pinkus GS, Longtine J, Shipp M, Kutok JL.No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma.Diagn Mol Pathol. 2009 Sep;18(3):144-9.
  • Abramson JS,Chen W,Juszczynski P,Takahashi H,Neuberg D,Kutok JL,Takeyama K,Shipp MA.The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.British Journal of Haematology. 2009 Feb;144(3):358-66.
  • Rodig SJ,Ouyang J,Juszczynski P,Currie T,Law K,Neuberg DS,Rabinovich GA,Shipp MA,Kutok JL.AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.Clin Cancer Res. 2008 Jun 1;14(11):3338-44.
  • Crump SR, Shipp MP, McCray GG, Morris SJ, Okoli JA, Caplan LS, Thorne SL, Blumenthal DS.Abnormal mammogram follow-up: do community lay health advocates make a difference?.Health Promot Pract. 2008 Apr;9(2):140-8.
  • Takeyama K, Monti S, Manis JP, Cin PD, Getz G, Beroukhim R, Dutt S, Aster JC, Alt FW, Golub TR, Shipp MA.Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas.Oncogene. 2008 Jan 10;27(3):318-22.
  • Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA.SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.Blood. 2008 Feb 15;111(4):2230-7.
  • Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A.BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.Blood. 2007 Sep 15;110(6):2067-74.
  • Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A.BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.Cancer Cell. 2007 Aug;12(2):171-85.
  • Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA.The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9.
  • Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP, Cancer FT, Leukemia GB.High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Leuk Lymphoma. 2007 May;48(5):870-80.
  • Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA.Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.J Clin Oncol. 2007 May 1;25(13):1741-6.
  • Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A.Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12.
  • Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL.Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.Am J Surg Pathol. 2007 Jan;31(1):106-12.
  • Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL.Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).Clin Cancer Res. 2006 Dec 1;12(23):7174-9.
  • Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA.Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.Blood. 2006 Nov 15;108(10):3428-33.
  • Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC, Shipp MA.BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate.Mol Cell Biol. 2006 Jul;26(14):5348-59.
  • Takahashi H, Feuerhake F, Kutok JL, Monti S, Dal Cin P, Neuberg D, Aster JC, Shipp MA.FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3265-71.
  • Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, Dalla-Favera R.Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.J Exp Med. 2006 Feb 20;203(2):311-7.
  • Takahashi H, Feuerhake F, Monti S, Kutok JL, Aster JC, Shipp MA.Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma.Blood. 2006 Jan 15;107(2):844-5.
  • Shipp MA, Aquino SL, Harris NL.Case Records of the Massachusetts General Hospital: A thirty year-old woman with fever and mediastinal mass.New England Journal of Medicine.:In press.
  • Feuerhake F, Kutok JL, Monti S, Chen W, Lacasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA.NF{kappa}B activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.Blood. 2005 Aug 15;106(4):1392-9.
  • Abramson JS, Shipp MA.Advances in the biology and therapy of diffuse large B-cell lymphoma-moving towards a molecularly targeted approach.Blood. 2005 Aug 15;106(4):1164-74. Review.
  • Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT.Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.Clin Cancer Res. 2005 May 1;11(9):3417-24.
  • Shipp MA, Aquino SL, Harris NL.Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal mass.N Engl J Med. 2005 Apr 21;352(16):1697-704.
  • Rodig SJ, Savage KJ, Nguyen V, Pinkus GS, Shipp MA, Aster JC, Kutok JL.TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas.Am J Surg Pathol. 2005 Feb;29(2):196-203.
  • Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC.The phosphodiesterase PDE4B limits cAMP associated, PI3K-AKT dependent, apoptosis in diffuse large B-cell lymphoma.Blood. 2005 Jan 1;105(1):308-16.
  • Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA.Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.Blood. 2005 Mar 1;105(5):1851-61.
  • Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M.Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.Leuk Lymphoma. 2004 Apr;45(4):761-7.
  • Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA.The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.Blood. 2003 Dec 1;102(12):3871-9.
  • Takeyama K, Aguiar RC, Gu L, He C, Freeman GJ, Kutok JL, Aster JC, Shipp MA.The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity.J Biol Chem. 2003 Jun 13;278(24):21930-7.
  • Lin TS, Howard OM, Neuberg DS, Kim HH, Shipp MA.Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.Leuk Lymphoma. 2002 Apr;43(4):793-7.
  • Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA.Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.J Clin Oncol. 2002 Mar 1;20(5):1288-94.
  • Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR.Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.Nat Med. 2002 Jan;8(1):68-74.
  • de Leval L, Ferry JA, Falini B, Shipp M, Harris NL.Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells?.Am J Surg Pathol. 2001 Oct;25(10):1277-82.
  • Wu E, Mari BP, Wang F, Anderson IC, Sunday ME, Shipp MA.Stromelysin-3 suppresses tumor cell apoptosis in a murine model.J Cell Biochem. 2001;82(4):549-55.
  • Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA.BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration.Blood. 2000 Dec 15;96(13):4328-34.
  • Aguiar RC, Yakushijin Y, Kharbanda S, Tiwari S, Freeman GJ, Shipp MA.PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest.Blood. 1999 Oct 1;94(7):2403-13.
  • Howard OM, Shipp MA.The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas.Curr Opin Oncol. 1998 Sep;10(5):385-91.
  • Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W, Anderson I, Shipp MA.A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma.Blood. 1998 Jun 1;91(11):4282-91.
  • Mari BP, Anderson IC, Mari SE, Ning Y, Lutz Y, Kobzik L, Shipp MA.Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism.J Biol Chem. 1998 Jan 2;273(1):618-26.
  • Ishimaru F, Mari B, Shipp MA.The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms.Blood. 1997 Jun 1;89(11):4136-45.
  • Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA.Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.J Clin Oncol. 1997 Apr;15(4):1631-7.
  • Ganju RK, Shpektor RG, Brenner DG, Shipp MA.CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase.Blood. 1996 Dec 1;88(11):4159-65.
  • Ishimaru F, Potter NS, Shipp MA.Phorbol ester-mediated regulation of CD10/neutral endopeptidase transcripts in acute lymphoblastic leukemias.Exp Hematol. 1996 Jan;24(1):43-8.
  • Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN.High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.J Clin Oncol. 1995 Dec;13(12):2916-23.
  • Anderson IC, Sugarbaker DJ, Ganju RK, Tsarwhas DG, Richards WG, Sunday M, Kobzik L, Shipp MA.Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts.Cancer Res. 1995 Sep 15;55(18):4120-6.
  • Ishimaru F, Shipp MA.Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements.Blood. 1995 Jun 1;85(11):3199-207.
  • Shipp MA.Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease?.Blood. 1994 Mar 1;83(5):1165-73.
  • Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA.Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies.Blood. 1993 Dec 15;82(12):3539-47.
  • Salles G, Rodewald HR, Chin BS, Reinherz EL, Shipp MA.Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo.Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7618-22.
  • King KA, Hua J, Torday JS, Drazen JM, Graham SA, Shipp MA, Sunday ME.CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides.J Clin Invest. 1993 May;91(5):1969-73.
  • Salles G, Chen CY, Reinherz EL, Shipp MA.CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis.Blood. 1992 Oct 15;80(8):2021-9.
  • Chen CY, Salles G, Seldin MF, Kister AE, Reinherz EL, Shipp MA.Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active site.J Immunol. 1992 May 1;148(9):2817-25.
  • Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Stein H, Sunday ME, Reinherz EL.CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10662-6.
  • Shipp MA, Stefano GB, D'Adamio L, Switzer SN, Howard FD, Sinisterra J, Scharrer B, Reinherz EL.Downregulation of enkephalin-mediated inflammatory responses by CD10/neutral endopeptidase 24.11.Nature. 1990 Sep 27;347(6291):394-6.